Causes and predictors of hospital readmissions in patients older than 65 years hospitalized for heart failure with preserved left ventricular ejection fraction in Eestern Romania

Clinical Interventions in Aging

Volumn 10, Issue , 2015, Pages 979-990

  Mavrea, Adelina Marioara ^a   Dragomir, Tiberiu ^a   Bordejevic, Diana Aurora ^a   Tomescu, Mirela Cleopatra ^a   Ancusa, Oana ^a   Marincu, Iosif ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Elderly; Heart failure with preserved left ventricular ejection fraction; Hospital readmissions

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HEART FAILURE WITH PRESERVED LEFT VENTRICULAR; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATHOGENESIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; ROMANIA; AGE; BLOOD; COMORBIDITY; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; STATISTICS AND NUMERICAL DATA;

AGE FACTORS; AGED; BIOMARKERS; COMORBIDITY; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PATIENT READMISSION; PROGNOSIS; ROMANIA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84934270411     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2010;121:e1–e170.
2. Formiga F, Chivite D, Sole A. Functional outcomes of elderly patients after the first hospital admission for decompensated heart failure. A prospective study. Arch Gerontol Geriatr. 2006;43:175–185.
3. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011;123: 2006–2013.
4. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with pre­served ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–271.
5. Jugdutt BI. Aging and remodeling during healing of the wounded heart: cur­rent therapies and novel drug targets. Curr Drug Targets. 2008;9:325–344.
6. Paulus WJ, Tschope C, Sanderson J, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539–2550.
7. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;392(suppl 1):1–266.
8. McMurray J, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012;33:1787–1847.
9. Montalescot G, Sechtern U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013;34:2949–3003.
10. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J. 2013;34: 2159–2219.
11. Vahnian A, Alfieri O, Andreotti F, et al. Guidelines on the manage­ment of valvular heart disease (version 2012). Eur Heart J. 2012;33: 2451–2496.
12. Tendera M, Aboyans V, Bartelink AM, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. Eur Heart J. 2011;32:2851–2906.
13. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–480.
14. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. Available from: https://www.idf.org/webdata/docs/WHO_IDF_definition_diagnosis_of_diabetes.pdf. Accessed Dec 10, 2012.
15. Blanc B, Finch CA, Hallberg L, et al. Nutritional anaemias. Report of a WHO Scientific Group. WHO Tech Rep Ser. 1968;405:1–40.
16. Decramer M, Vestbo J, Bourbeau J, et al. Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease (GOLD); 2013. Available from: www.goldcopd.org. Accessed Feb 20, 2013.
17. Lang RM, Bierig M, Devereux RB, et al; Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiogra­phy, Recommendation for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–1463.
18. Rao A, Asadi-Lari M, Walsh J, Wilcox R, Gray D. Quality of life in patients with signs and symptoms of heart failure – does systolic func­tion matter? J Card Fail. 2006;12:677–687.
19. Fahrenberg J, Myrtek M, Schumacher J, Brähler E. Fragebogen zur Lebenszufriedenheit (FLZ) [Questionnaire regarding life quality (Pocket Guide)]. Handanweisung. Göttingen: Hogrefe; 2000.
20. Demers C, McKelvie RS, Negassa A, Yusut S. Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. Am Heart J. 2001;142:698–703.
21. Schwartz JB, Zipes DP. Cardiovascular disease in the elderly. In: Libby P, Bonow RO, Mann DL, Zipes DP, editors. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. Vol. 2. Pennsylvania, PA: Saunders Elsevier; 2012:1727–1756.
22. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114:397–403.
23. Flather MD, Shibata MC, Coats AJ, et al; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–225.
24. Fonarow GC, Stough WG, Abraham WT, et al; OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50:768–777.
25. World Health Organization. Definition of an older or elderly person. Geneva, Switzerland: WHO; 2010. Available from: http://www.who.int/healthinfo/survey/ageingdefnolder/en/index.html. Accessed November 22, 2010.
26. Felker GM, Hasselblad V, Hernandez AF, O’Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis or randomized controlled trials associated with a significant reduction in all-cause mortality compared to usual care in patients with chronic heart failure. Am Heart J. 2009;158:422–430.
27. Karogeropoulos A, Georgeopoulou V, Psaty BM. Inflammatory markers and incident heart failure risk in older adults: the health, aging, and body composition study. J Am Coll Cardiol. 2010;55(19):2129–2137.
28. Yusuf S, Pfeffer MA, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362(9386):777–781.
29. Win S, Anand I, McMurray J, et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction. Result from the I-preserve trial. J Am Coll Cardiol. 2013;61(10):1498–1506.
30. Lenzen MJ, Scholte op Reimer WJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular func­tion: a report from the EuroHeart Failure Survey. Eur Heart J. 2004;25(14):1214–1220.
31. Hamdani N, Paulus WJ, van Heerebeek L, et al. Distinct myocar­dial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction. Eur Heart J. 2009;30:1863–1872.
32. Reil JC, Hohl M, Reil GH, et al. Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J. 2013;34(36):2839–2949.
33. Kosmala W, Wang M, Wang T, et al. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC. 2013;62(15): 1330–1338.
34. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10:933–989.
35. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth. J Am Coll Cardiol. 2010;55:526–537.
36. Van Velhuisen DJ, Linssen GC, Jaarma T, et al. B-type natriuretic pep­tide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013;61(14):1498–1506.
37. Cleland JG, Tendera M, Adamus J, et al; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–2345.
38. Pitt B, Pfeffer MA, Assmann SF, et al; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction (TOP­CAT). N Engl J Med. 2014;370:1383–1392.
39. Ghio S, Magrini G, Serio A, et al; SENIORS Investigators. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J. 2006;27:562–568.
40. Putko BN, Wang Z, Lo J, et al, on behalf of the Alberta HEART Inves­tigators. Circulating Levels of Tumor Necrosis Factor-Alpha Receptor 2 Are Increased in Heart Failure with Preserved Ejection Fraction Relative to Heart Failure with Reduced Ejection Fraction: Evidence for a Divergence in Pathophysiology. PLoS One. 2014;9(6):e99495.
41. Tehrani F, Phan A, Chien CV, Morrissey RP, Rafique AM, Schwarz ER. Value of medical therapy in patients <80 years of age with heart failure and preserved ejection fraction. Am J Cardiol. 2009;103:829–833.